Holoclara is a immunotherapy company that offers autoimmune disorders with nematode derived molecules.
Holoclara has raised $16.0M in total funding. The most recent round was Series A. The last funding was announced in June 2024.
Holoclara's investors include Kairos Ventures, Freeflow Ventures, Endurance28, Bold Capital Partners, Horizons Ventures.
Holoclara is headquartered in Los Angeles, United States.
Holoclara is a immunotherapy company that offers autoimmune disorders with nematode derived molecules.
Holoclara is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Holoclara — Funding & Investors." VCBacked, June 27, 2024, https://www.vcbacked.co/company/holoclara. Accessed August 23, 2026.
VCBacked. (2024). Holoclara — Funding & Investors. Retrieved August 23, 2026, from https://www.vcbacked.co/company/holoclara
{{cite web |title=Holoclara — Funding & Investors |url=https://www.vcbacked.co/company/holoclara |website=VCBacked |access-date=August 23, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated